Skip to main content
2026 Annual Assembly of Hospice & Palliative Care Main banner
Conference Favorites
This is not in your schedule.
This will appear in your schedule. Click again to remove it.
Session Icons
AAHPM Abstract Award Winner
AAHPM Abstract Award Winner
HPNA Abstract Award Winner
HPNA Abstract Award Winner
Registration Required
Registration Required
Poster Icons
AAHPM Abstract Award Winner
AAHPM Abstract Award Winner
HPNA Abstract Award Winner
HPNA Abstract Award Winner

2026 Annual Assembly of Hospice and Palliative Care

P03 What Every Expert Should Know: Advanced Pharmacologic Approaches in Hospice and Palliative Care

Wednesday, March 4, 2026
8:00am - 5:00pm PST
Location: Room 33 ABC
Disclosure(s):
Mary Lynn McPherson, PharmD PhD FAAHPM: No financial relationships to disclose
Alexandra L. McPherson, PharmD, MPH: No financial relationships to disclose
Eric Widera, MD: No financial relationships to disclose
Jeremy M. Hirst, MD: No financial relationships to disclose
Maximillian Stevenson, PharmD, MA, BCPS: No financial relationships to disclose
This full-day preconference offers an in-depth, case-based exploration of complex pharmacologic strategies essential to expert-level hospice and palliative care. Building on foundational knowledge, faculty will guide participants through advanced applications of symptom management, including nuanced opioid titration, safe and effective use of adjuvant analgesics, deprescribing in multimorbidity, and pharmacologic considerations in organ dysfunction. Special attention will be given to controversial and evolving areas of practice. Through interactive scenarios, expert panel discussion, and real-world clinical challenges, participants will refine their pharmacologic decision-making and strengthen their ability to tailor therapy for patients with complex needs.

This is a must-attend session for experienced clinicians seeking to elevate pharmacologic competence, apply the latest evidence and expert consensus to practice, and contribute to safer, more effective medication management across care settings.

Learning Objectives:

  • Describe the drug therapy selection process, and deprescribing process in serious illness.
  • Given a simulated case, describe potential therapeutic options in the management of neurologic symptoms and Alzheimer’s disease.
  • Describe best practices in the use of buprenorphine in caring for seriously ill patients.
  • Explain the latest consensus guidance on opioid conversion calculations.
  • Describe the outcomes of several pharmacotherapy trials involving the treatment of seriously ill patients.